Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2020

View Archived Issues

Pivotal Japanese study evaluates zandelisib for indolent NHL

First-in-human data presented for BAY-1895344

Positive data from phase IIa NASH study of PXL-770

ZLY-16 shows hepatoprotective effects in mouse model of NASH

Vascular endothelial cells are active co-conspirators in metastasis

Discovery of new allosteric inhibitors of deoxyhypusine synthase

Enanta Pharmaceuticals patents new antivirals

E-Scape Bio discloses LRRK2 inhibitors

Merck & Co. identifies new HDAC inhibitors

New ENPP1 inhibitors presented by Stingray Therapeutics

Lead Discovery Center and SOTIO patent new compounds for cancer

Neural stem cells open to alternate fates

Preliminary first-in-human data presented for CLN-081

European Commission approves Crysvita for adolescents and adults with XLH

MEN-1611 plus trastuzumab +/- fulvestrant well tolerated in phase I breast cancer trial

Revelation Biosciences receives ethics committee approval for phase I study of REVTx-99 for COVID-19

Results reported from nextMONARCH and monarchE studies of abemaciclib

GB-004 advances into phase II for ulcerative colitis

Sorrento initiates phase I study of COVI-GUARD in patients with moderate COVID-19

No delay in progression of ovarian cancer seen with cancer vaccine MVA-5T4 in clinical trial

Xencor presents initial phase I data on tidutamab in neuroendocrine tumors

Ovoca's BP-101 for decreased sexual desire in women not approved in Russia

Phase IIb study of SYN-010 in IBS-C to be discontinued

Apellis advances pegcetacoplan into registrational programs for C3G/IC-MPGN and ALS

IND in effect for Fulcrum's phase I study of FTX-6058 for sickle cell disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...